ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31

ORAMED PHARMACEUTICALS INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$4.06−0.01 (-0.25%)

Close on Oct 19, 2026

Market cap: $172.56M
P/E (TTM): 1.0
Dividend yield: 6.16%

ORAMED PHARMACEUTICALS INC. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2021 2021-08-31	FY 2020 2020-08-31	FY 2019 2019-08-31	FY 2018 2018-08-31	FY 2017 2017-08-31	FY 2016 2016-08-31	FY 2015 2015-08-31	FY 2014 2014-08-31	FY 2013 2013-08-31	FY 2012 2012-08-31	FY 2011 2011-08-31	FY 2010 2010-08-31	FY 2009 2009-08-31	FY 2008 2008-08-31	FY 2007 2007-08-31
Cash & Equivalents	46	54	9.06	77	19	3.33	5.00	3.97	3.91	3.21	1.76	2.27	4.43	1.51	1.20	1.72	–	–
Short-Term Investments	5.42	3.44	58	5.85	3.30	3.70	4.59	2.86	2.86	2.09	1.05	0.96	0.20	0.38	–	–	–	–
Cash & Short-Term Investments	51	58	67	83	23	7.03	9.59	6.83	6.76	5.30	2.81	3.23	4.63	1.90	1.20	1.72	–	–
Receivables	–	–	–	–	–	–	–	–	–	–	–	–	0.09	0.54	–	–	–	–
Prepaid Expenses & Other	2.74	1.29	0.54	–	0.61	1.04	0.57	0.16	0.20	0.13	0.06	0.09	0.09	0.00	–	–	–	–
Other Current Assets	–	–	–	–	–	–	–	–	–	–	–	0.03	0.04	–	–	–	–	–
Total Current Assets	133	143	163	95	41	33	31	20	31	17	22	8.64	5.28	4.28	–	–	–	–
Property, Plant & Equipment	0.59	0.70	0.87	0.40	0.10	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.00	0.02	–	–	–	–
Gross Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	0.15	0.14	0.13	0.13	0.12	–	–	–	–
Accumulated Depreciation	–	–	–	–	–	–	–	–	–	-0.13	-0.13	-0.12	-0.12	-0.11	–	–	–	–
Long-Term Investments	8.37	3.52	1.81	6.69	3.93	1.30	2.79	0.00	0.00	0.00	0.00	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.75	0.41	0.69	0.53	0.08	0.17	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	0.04	0.03	0.03	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Assets	231	155	221	128	45	35	47	39	43	26	22	8.66	5.29	4.33	–	–	–	–
Accounts Payable	0.44	0.79	0.55	3.79	1.70	2.54	2.06	2.72	1.41	0.95	0.93	0.43	0.60	0.38	–	–	–	–
Accrued Expenses	1.08	0.40	0.61	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Short-Term Debt	–	–	51	–	–	2.70	2.45	–	–	–	–	–	–	–	–	–	–	–
Current Debt	–	–	51	–	–	2.70	2.45	–	–	–	–	–	–	–	–	–	–	–
Current Portion of Leases	0.29	0.22	0.27	0.13	0.04	–	–	–	–	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	3.29	3.20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	1.35	–	–	2.00	2.00	2.70	2.45	2.45	2.16	0.50	–	–	–	–	–	–	–	–
Other Current Liabilities	1.71	1.37	0.06	0.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	19	5.69	53	6.68	4.54	5.31	4.55	5.17	3.62	1.49	0.97	0.50	0.64	0.44	–	–	–	–
Long-Term Leases	0.54	0.16	0.34	0.40	0.03	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0.83	0.37	0.61	0.53	0.03	0.17	–	–	–	–	–	–	–	–	–	–	–	–
Deferred Tax Liabilities	7.91	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	–	0.06	0.06	–	0.21	0.27	0.31	0.44	0.39	–	–	–	–	–	–	–	–	–
Total Liabilities	31	9.93	58	11	12	15	16	19	17	1.53	1.01	0.53	1.52	0.60	–	–	–	–
Total Debt	–	–	51	–	–	2.70	2.45	–	–	–	–	–	–	–	–	–	–	–
Common Stock	0.47	0.48	0.49	0.42	0.28	0.21	0.21	0.16	0.16	0.14	0.12	0.10	0.08	0.07	–	–	–	–
Additional Paid-In Capital	323	322	321	230	125	100	99	75	72	59	48	30	22	18	–	–	–	–
Retained Earnings	-123	-177	-158	-115	-93	-81	-69	-56	-46	-35	-28	-22	-18	-15	–	–	–	–
Comprehensive Income & Other	–	–	–	–	–	–	0.70	0.40	0.11	0.56	0.45	0.30	–	–	–	–	–	–
Shareholders' Equity	200	146	164	116	33	19	31	19	26	25	21	8.13	3.78	3.72	0.83	2.75	4.59	0.51
Noncontrolling Interest	–	-0.92	-0.93	0.74	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Equity	200	145	163	117	33	19	31	19	26	25	21	8.13	3.78	3.72	0.83	2.75	4.59	0.51
Total Liabilities & Equity	231	155	221	128	45	35	47	39	43	26	22	8.66	5.29	4.33	–	–	–	–
Shares Outstanding(shares)	39	40	40	35	24	17	17	14	13	12	10	7.94	6.67	5.84	–	–	–	–
Deposits	–	–	–	–	–	–	–	–	-11	-8.02	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 0.7%
Operating margin: -726.2%
Net margin: 8743.5%
Return on equity, FY2025: 37.0%

Financial strength

Current ratio: 4.98
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 142.1%

Valuation

P/E ratio: 1.0
Price to sales: 86.28
Price to book: –
Dividend yield: 6.16%